Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients

Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients

Abstract The tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR), such as osimertinib and gefitinib, aumolertinib have been widely used in EGFR mutation‐positive non‐small cell lung cancer (NSCLC) patients. However, the discrepancy of pharmacokinetic features and distributio...

Full description

Bibliographic Details
Main Authors: Ran Ren, Jiangang Zhang, Yongpeng He, Xianghua Zeng, Yu Zhou, Luyao Shen, Yongsheng Li, Dairong Li, Huakan Zhao
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:MedComm – Oncology
Subjects:
aumolertinib
EGFR‐TKIs
gefitinib
non‐small cell lung cancer
osimertinib
pharmacokinetics
Online Access:https://doi.org/10.1002/mog2.70002

Internet

https://doi.org/10.1002/mog2.70002

Similar Items